RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Invited Commentary: Studying the coagulopathy of COVID-19 – The Lancet

Commentary from the author on Twitter (thread – click for more)

RECOVERY Publication: ASPIRIN
(a widely used anti-platelet treatment in other settings)

14 892 patients hospitalised with COVID-19.

No impact on mortality.
Small improvement in hospital stay.
No impact on need for mechanical ventilation
6 more bleeds. 6 fewer thromboses (clots) pic.twitter.com/LxDzudss9F

— Martin Landray (@MartinLandray) November 18, 2021